Date | Price Target | Rating | Analyst |
---|---|---|---|
9/17/2024 | $8.00 → $10.00 | Hold | Jefferies |
2/29/2024 | $22.00 | Overweight | Cantor Fitzgerald |
2/26/2024 | $17.00 | Market Perform | Leerink Partners |
1/17/2024 | $33.00 → $22.00 | Buy → Neutral | DA Davidson |
1/3/2024 | $26.00 | Overweight | Barclays |
4/12/2023 | $25.00 | Equal-Weight | Stephens |
2/23/2023 | $34.00 | Market Perform → Outperform | SVB Securities |
10/24/2022 | Sell → Neutral | Guggenheim |
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the availability of comprehensive mental healthcare for children, adolescents, and their families. The innovative offering, in partnership with Brightline, is offered through Teladoc Health's virtual "front door," connecting members to the healthcare they need, and increasing access to mental healthcare providers specifically trained in pediatric, adolescent and family mental health. Supporting members under the age of 18 and caregivers across a wide range of conditions and degrees of mental health concerns, this solution will help children and parents better manage mental health conditions and navigate challengin
Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:TDOC) with a In-Line and lowers the price target from $14 to $10.
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company’s impressive second-quarter delivery numbers. The Tesla Trade Ark Invest reduced its stake in Tesla across its ARK Innovation ETF (NYSE:ARKK), selling 13,213 shares. This transaction came as a surprise, given that Tesla’s shares had recently soared 10.20% on Tuesday, marking the best intraday session since late April. Notably, on Tuesday, Ark Invest sold Tesla shares worth $14.5 million. The boost was primarily driven by the Elon Musk-led company’s second-quarter performance. Tesla reported 443,956 delive
SC 13G - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
SC 13G/A - Teladoc Health, Inc. (0001477449) (Subject)
8-K - Teladoc Health, Inc. (0001477449) (Filer)
144 - Teladoc Health, Inc. (0001477449) (Subject)
144 - Teladoc Health, Inc. (0001477449) (Subject)
Jefferies reiterated coverage of Teladoc with a rating of Hold and set a new price target of $10.00 from $8.00 previously
Cantor Fitzgerald initiated coverage of Teladoc with a rating of Overweight and set a new price target of $22.00
Leerink Partners initiated coverage of Teladoc with a rating of Market Perform and set a new price target of $17.00
PURCHASE, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 ("Second Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 ("Second Quarter 2023"). Financial and Operational Highlights for Second Quarter 2024 Second Quarter 2024 revenue of $642.4 million, down 2% year-over-yearSecond Quarter 2024 net loss of $837.7 million, or $4.92 per share, including a goodwill impairment charge of $790.0 million, or $4.64 per shareSecond Quarter 2024 adjusted EBITDA of $89.5 million, up 24%
PURCHASE, NY, July 17, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, announced that it will release second quarter 2024 results on Wednesday, July 31, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 453227. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/conferencing/global-numbers?confId=68682. A live audio webcast will also be avai
PURCHASE, NY, April 25, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 ("First Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 ("First Quarter 2023"). Financial and Operational Highlights for First Quarter 2024 First Quarter 2024 revenue grows 3% year-over-year to $646.1 millionFirst Quarter 2024 net loss of $81.9 million, or $0.49 per shareFirst Quarter 2024 adjusted EBITDA of $63.1 million, up 20% year-over-year "We are pleased to report a solid start to the year, with strength
PURCHASE, NY, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that it issued an inducement award to a new employee. Effective September 1, 2024, in connection with commencing employment as Senior Vice President of Product, BetterHelp, Terre Layton was granted an award of restricted stock units covering 50,000 shares of Teladoc Health's common stock, par value $0.001 per share. The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The
Harmonic Growth Partners, a leading expansion-stage investment firm that uniquely combines experienced investors with world-class technology CEOs, is excited to announce the addition of Daniel Vernic to its investment team as a Principal. Daniel's addition underscores Harmonic's commitment to offering market-leading, rapidly scaling technology companies a highly differentiated and valuable investment partner. Based in San Francisco, Daniel spent the first five years of his career at Goldman Sachs, where he worked in both equity and fixed income financial markets. Daniel holds a Bachelor of Arts from Bucknell University and an M.B.A. from the University of Virginia Darden School of Busines
PURCHASE, NY, July 31, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 ("Second Quarter 2024"). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 ("Second Quarter 2023"). Financial and Operational Highlights for Second Quarter 2024 Second Quarter 2024 revenue of $642.4 million, down 2% year-over-yearSecond Quarter 2024 net loss of $837.7 million, or $4.92 per share, including a goodwill impairment charge of $790.0 million, or $4.64 per shareSecond Quarter 2024 adjusted EBITDA of $89.5 million, up 24%
4 - Teladoc Health, Inc. (0001477449) (Issuer)
3 - Teladoc Health, Inc. (0001477449) (Issuer)
4 - Teladoc Health, Inc. (0001477449) (Issuer)
Jason Gorevic to depart the company, effective immediatelyCFO Mala Murthy appointed acting chief executiveTeladoc Health reaffirms guidance PURCHASE, NY, April 05, 2024 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departing the company, effective immediately. The Board of Directors has appointed Mala Murthy acting Chief Executive Officer while it searches for Mr. Gorevic's permanent successor. Ms. Murthy is a seasoned industry leader who has served as the Company's Chief Financial Officer since 2019, and she will continue serving in this role during this transition period. The Board has ret
PURCHASE, NY, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company's board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board's compensation committee. David B. Snow, Jr., non-executive Chairman of the company's board,
After spending two decades successfully scaling multiple healthcare technology companies, Perez joins Big Health to accelerate the commercial coverage and reimbursement for digital therapeutics Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced the appointment of Gabriela Perez as Chief Commercial Officer. In her new role, Perez will oversee Big Health's global commercial growth and strategy, including sales, client management, strategic partnerships, and new markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203005297/en/Big Health Chief Commercial Office